3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
10
Salivary Gland Neoplasms
2
Ovarian Neoplasms
2
Multiple Myeloma
2
Lymphoma
2
Hematologic Neoplasms
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Brain Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Hemangiosarcoma
1
HER2-positive Metastatic Breast Cancer
1
HER2-positive Breast Cancer
1
HER2-Positive Primary Breast Cancer
1
Glioma
1
Interventions
fludarabine
10
ruxolitinib
9
fludarabine phosphate
9
Whole-Body Irradiation
9
Specimen Handling
9
Cyclophosphamide
8
Azacitidine
8
Mycophenolic Acid
7
Cytarabine
7
Busulfan
7
Biopsy
7
Tacrolimus
6
venetoclax
5
Stem Cell Transplantation
5
Sirolimus
5
Peripheral Blood Stem Cell Transplantation
5
Injections
5
Granulocyte Colony-Stimulating Factor
5
Melphalan
4
Cyclosporine
4
CPX-351
4
luspatercept
3
ivosidenib
3
decitabine and cedazuridine drug combination
3
Thiotepa
3
Methotrexate
3
Liposomes
3
Idarubicin
3
Daunorubicin
3
Cyclosporins
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Myeloproliferative Disorders
×
Ado-Trastuzumab Emtansine
×
90 days
×
Clear all
No trials found.